WO2018065365A1 - Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 - Google Patents

Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 Download PDF

Info

Publication number
WO2018065365A1
WO2018065365A1 PCT/EP2017/074983 EP2017074983W WO2018065365A1 WO 2018065365 A1 WO2018065365 A1 WO 2018065365A1 EP 2017074983 W EP2017074983 W EP 2017074983W WO 2018065365 A1 WO2018065365 A1 WO 2018065365A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
4alkyl
group
membered
halo
Prior art date
Application number
PCT/EP2017/074983
Other languages
English (en)
Inventor
Tongfei Wu
Dirk Brehmer
Lijs Beke
An Boeckx
Gaston Stanislas Marcella Diels
Edward Charles LAWSON
Lieven Meerpoel
Vineet PANDE
Marcus Cornelis Bernardus Catharina PARADÉ
Wim Bert Griet Schepens
Weimei SUN
Johannes Wilhelmus John F. Thuring
Marcel Viellevoye
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112019006414A priority Critical patent/BR112019006414A2/pt
Priority to CA3037998A priority patent/CA3037998A1/fr
Priority to AU2017338269A priority patent/AU2017338269B2/en
Priority to CN202211277466.7A priority patent/CN115626935A/zh
Priority to TNP/2019/000087A priority patent/TN2019000087A1/en
Priority to US16/336,934 priority patent/US11098062B2/en
Priority to JP2019517909A priority patent/JP7101171B2/ja
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to CN201780061258.4A priority patent/CN109803971B/zh
Priority to MX2019003843A priority patent/MX2019003843A/es
Priority to UAA201904546A priority patent/UA124074C2/uk
Priority to EP17781060.3A priority patent/EP3519413A1/fr
Priority to KR1020197012099A priority patent/KR102531344B1/ko
Priority to EA201990851A priority patent/EA201990851A1/ru
Publication of WO2018065365A1 publication Critical patent/WO2018065365A1/fr
Priority to IL265718A priority patent/IL265718B/en
Priority to PH12019500731A priority patent/PH12019500731A1/en
Priority to US17/378,417 priority patent/US20210371433A1/en
Priority to JP2022033419A priority patent/JP2022084699A/ja
Priority to US18/488,626 priority patent/US20240124493A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel monocyclic and bicyclic ring system substituted carbanucleoside analogues useful as PRMT5 inhibitors.
  • the invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
  • PRMT5 also described as Hsl7, Jbpl, Skbl, Capsuleen or Dart5
  • Hsl7, Jbpl, Skbl, Capsuleen or Dart5 is one of the major methyltransferases responsible for mono- and symmetric dimethylation of arginines.
  • Post-translational arginine methylation on histones and non-histone proteins seems to be crucial for a variety of biological processes, like genome organisation, transcription, differentiation, spliceosome function, signal transduction and regulation of cell-cycle progression, stem cells and T-cell fate [Stopa, N. et al, Cell Mol Life Sci, 2015. 72(11): p. 2041-59] [Geoghegan, V. et al, Nat Commun, 2015. 6: p. 6758].
  • Metazoan PRMT5 forms a functional complex with the methylosome protein 50 (MEP50) also named as Wdr77, androgen receptor coactivator p44 and Valois. Both, elevated PRMT5-MEP50 protein level and cytoplasmic accumulation are implicated in cancer tumorigenesis and have recently been correlated with poor clinical outcome [Shilo, K. et al, Diagn Pathol, 2013. 8: p. 201]. Cellular rescue experiments that addressed both the catalytic and scaffold function of the PRMT5-MEP50 complex, beside comprehensive enzymo logical studies have substantiate the oncogenic link between protein level, localisation and enzymatic function [Gu, Z. et al, Biochem J, 2012. 446(2): p.
  • PRMT5 is a member of the type II PRMT subfamily that utilises S-adenosylmethionine (SAM) to generate symmetric dimethylated arginine on histones and non-histone protein substrates and S-adenosylhomocysteine (SAH).
  • SAM S-adenosylmethionine
  • SAH S-adenosylhomocysteine
  • PRMT5 human hetereo-octameric complex
  • MEP50 histone H4 peptide substrate
  • PRMT5 activity occurs through a vast number of different binding partners, post-translational modification cross talk, miRNAs and subcellular localisation. Methylation of histones H2A and H4 on Arg3 and histone H3 on Arg8 regulate chromatin organisation for specific repression of gene transcripts that are involved in differentiation, transformation, cell-cycle progression and tumour suppression [Karkhanis, V. et al., Trends Biochem Sci, 2011. 36(12): p. 633-41]. Furthermore, PRMT5 -mediated methylation of histone H4 on Arg3 might recruit the DNA- methyltransferase DNMT3 A to couple histone and DNA methylation for long-term gene silencing [Zhao, Q. et al, Nat Struct Mol Biol, 2009. 16(3): p. 304-11].
  • Non-histone methylation can occur either in the cytoplasm or nucleus dependent on the cellular localisation of PRMT5.
  • Further evidence for PRMT5 involved in splicing has been provided by the conditional PRMT5 knockout in mouse neural stem cells. Cells that lack PRMT5 showed a selective retention of introns and skipping of exons with weak 5 ' donor sites [Bezzi, M. et al, Genes Dev, 2013. 27(17): p. 1903-16].
  • PRMT5 influences key pathways involved in cell fate and homeostasis by direct methylation of key signalling nodules like p53 [Jansson, M. et al, Nat Cell Biol, 2008. 10(12): p. 1431-9], EGFR [Hsu, J.M. et al, Nat Cell Biol, 2011. 13(2): p. 174-81], CRAF [Andreu-Perez, P. et al, Sci Signal, 2011. 4(190): p. ra58], PI3K/AKT [Wei, T.Y. et al, Cell Signal, 2014. 26(12): p. 2940-50], NFKB [Wei, H. et al., Proc Natl Acad Sci U S A, 2013. 110(33): p. 13516-21].
  • PRMT5 is one of the major sym-Arg methyltransferases and involved in a multitude of cellular processes, an increased protein expression appears to be an important factor in its tumourigenicity.
  • MCL mantle cell lymphoma
  • miRNAs the translation of PRMT5 in mantle cell lymphoma (MCL) seems to be regulated by miRNAs.
  • MCL cells show less mRNA and a slower transcription rate of PRMT5 than normal B lymphocytes, the PRMT5 level and the methylation of H3R8 and H4R3 are significantly increased [Pal, S. et al, EMBO J, 2007. 26(15): p. 3558-69].
  • PRMT5 is considered as a clinical relevant target, very few selective PRMT5 inhibitors have been published, yet. Very recently, a novel sub-nano molar potent PRMT5 inhibitor (EPZ015666) with anti-tumour activity in multiple MCL xenograft models has been described to be the first chemical probe suitable for further validation of PRMT5's biology and role in cancer [Chan-Penebre, E. et al., Nat Chem Biol, 2015. 11(6): p. 432- 7] ⁇
  • WO2016135582 and US20160244475 describe substituted nucleoside derivatives useful as anticancer agents.
  • WO2014100695A1 discloses compounds useful for inhibiting PRMT5 activity
  • WO2014100730A1 discloses PRMT5 inhibitors containing a dihydro- or
  • WO2003070739 discloses partial and full agonists of Al adenosine receptors, their preparation, and their therapeutic use.
  • WO2012082436 discloses compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.
  • WO2014100719 discloses PRMT5 inhibitors and uses thereof.
  • WO03074083 discloses combination therapies that selectively kill methylthioadenosine phosphorylase deficient cells. Analogs of MTA are described herein as anti-toxicity agents.
  • WO2012075500 discloses 7-deazapurine modulators of histone methyltransferase.
  • WO2014035140 discloses compounds and compositions for modulating histone methyltransferase activity.
  • WO2015200680 describes PRMT5 inhibitors and uses thereof.
  • WO9640686 describes heterocyclic substituted cyclopentane compounds and methods of using such compounds for inhibiting adenosine kinase.
  • WO2017032840 relates to novel 6-6 bicyclic aromatic ring substituted nucleoside analogues useful as PRMT5 inhibitors. There is thus a strong need for novel PRMT5 inhibitors thereby opening new avenues for the treatment or prevention of cancer, such as e.g. mantle cell lymphoma. It is accordingly an object of the present invention to provide such compounds.
  • the compounds of the present invention are structurally different and may have improved properties such as for example improved potency, or improved
  • PK pharmacokinetics
  • oral bioavailability compared with compounds disclosed in the prior art.
  • the compounds of the present invention are useful as PRMT5 inhibitors.
  • the compounds according to the invention and compositions thereof may be useful for the treatment or prevention, in particular for the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • the present invention concerns novel compounds of Formula (I):
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci-4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system;
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C3- 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention also concerns methods for the preparation of compounds of the present invention and pharmaceutical compositions comprising them.
  • the compounds of the present invention were found to inhibit PRMT5 per se or can undergo metabolism to a (more) active form in vivo (prodrugs), and therefore may be useful in the treatment or prevention, in particular in the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof may be suitable in the treatment or prevention, in particular in the treatment, of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • the present invention also concerns the use of compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5, for the treatment or prevention of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • substituted is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using
  • substituted are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
  • substituents When two or more substituents are present on a moiety they may, unless otherwise is indicated or is clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.
  • Ci-4alkyl group contains from 1 to 4 carbon atoms
  • Ci_3alkyl group contains from 1 to 3 carbon atoms and so on.
  • halo as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated or is clear from the context.
  • Ci-4alkyl refers to a hydrocarbyl radical of Formula Cn bn+i wherein n is a number ranging from 1 to 4.
  • Ci-4alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
  • Ci-4alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain.
  • Ci-4alkyl includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes methyl, ethyl, n-propyl, /-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, /sobutyl and /er/-butyl), and the like.
  • the skilled person will realize that the term 'Ci-4alkoxy' or 'Ci-4alkyloxy' as a group or part of a group refers to a radical having the Formula -OR c wherein R c is Ci-4alkyl.
  • Ci-4alkyloxy examples include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy and tert-butyloxy.
  • C2-4alkenyl as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 4 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, l-propen-2-yl, and the like.
  • C2-6alkenyl as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, pentenyl, l-propen-2-yl, hexenyl and the like.
  • 'C3-6cycloalkyl' as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • 'C5-6cycloalkyl' as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 5 to 6 carbon atoms such as cyclopentyl or cyclohexyl.
  • Z is -CR 5e R 5g -CR 5i R 5h -, it is intended that the C-atom with the R 5e and R 5g substituents is attached to Ar.
  • a substituent on a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms may replace any hydrogen atom on a ring carbon atom or where possible on a ring nitrogen atom (in which case a hydrogen on a nitrogen atom may be replaced by a substituent).
  • heteroatoms may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified.
  • typical 4- to 7-membered monocyclic aromatic rings will be 5- or 6- membered monocyclic aromatic rings such as for example pyrrolyl, pyridinyl, furanyl, and the like.
  • Ar represents imidazolyl it may be attached to the remainder of the molecule via a ring carbon or ring nitrogen atom.
  • Non-limiting, examples of the Ar group being a 9-membered. bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N, are
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein a nitrogen atom replaces one of the two fused carbon atoms in the Ar group, a carbonyl group is present in said bicyclic aromatic ring system as exemplified by the structure shown below:
  • Ar group being a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom, are shown below:
  • Non-limiting examples of the Ar group being a fused bicyclic partially aromatic ring system which is attached with the aromatic ring to linker Z, are shown below:
  • subject refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.
  • therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • treatment is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total eliminat ion of all symptoms.
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganisation of some of the bonding electrons.
  • any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherw ise indicated as having a particular configuration (e.g. R, S) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers.
  • R, S a particular configuration
  • any particular chiral atom is not specified in the structures shown herein, then all stereoisomers are contemplated and included as the compounds of the invention, either as a pure stereoisomer or as a mixture of two or more stereoisomers.
  • stereochemistry is specified by bonds which are shown as sol id wedged or hashed wedged bonds, or are otherwise indicated as having a particular configuration (e.g. R, 5), then that stereoisomer is so specified and defined. It will be clear this also applies to subgroups of Formula ( I ). It follows that a single compound may, where possible, exist in both stereoisomeric and tautomeric form.
  • stereoisomers ' " stereoisomeric forms” or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.
  • Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
  • a 1 : 1 mixture of a pair of enant iomers is a racemate or racemic mixture.
  • Atropisomers are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance.
  • Al l atropisomeric forms of the compounds of Formula ( I ) are intended to be included within the scope of the present invent ion.
  • Diastereomers are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. Substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or tran s-con figu rat io n ; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configurat ion. Therefore, the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
  • the absolute configuration is specified according to the Cahn-lngold-Prelog system.
  • the configuration at an asymmetric atom is specified by either R or S.
  • Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers.
  • a compound of Formula (I) is for instance specified as ( R)
  • a compound of Formula (I) is for instance specified as E
  • this means that the compound is substantially free of the Z isomer
  • a compound of Formula ( I ) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
  • salts of the compounds of Formula (I) and solvates thereof are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutical ly acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • Al l salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • Ph armaceu t icall y-acceptab 1 e salts include acid addition salts and base addition salts. Such salts may be formed by convent ional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration ). Salts may also be prepared by exchanging a counter-ion of a compound of the invent ion in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • compositions of Formula ( I ) and solvates thereof are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula ( I ) and solvates thereof, are able to form.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic ( i.e. ethanedioic ), ma Ionic, succinic ( i.e.
  • butanedioic acid maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p- toluenesulfonic, cyclamic, salicylic, p-aminosalicyl ic, pamoic and the like acids.
  • salt forms can be converted by treatment with an appropriate base into the free base form.
  • the compounds of Formula ( I ) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the l ithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine.
  • organic bases e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine.
  • dipropylaminc diisopropylaminc, di-n-butylaminc, pyrrolidine, piperidine, morpholinc, trimethylamine, triethylamine, tripropylamine, quinuclidinc, pyridine, quinoline and isoquinoline; the benzathine, -methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • the salt form can be converted by treatment with acid into the free acid form.
  • prodrugs are also included within the scope of the invention.
  • prodrug of a relevant compound of the invention includes any compound that, following oral or parenteral administration, in particular oral administration, is metabolised in vivo to a form that compound in an experimentally-detectable amount, and w ithin a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily) ).
  • parenteral administration includes al l forms of administration other than oral administration, in particular intravenous ( IV ), intramuscular (IM), and subcutaneous (SC) inject ion.
  • Prodrugs may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is
  • prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfliydryl, carboxy or carbonyl group in a compound of the invent ion is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, sulfliydryl, carboxy or carbonyl group, respectively; in part icular wherein a hydroxyl group in a compound of the invention is bonded to any group (e.g. that may be cleaved in vivo to regenerate the free hydroxyl.
  • prodrugs in particular are compounds of Formula (I) or subgroups thereof wherein R 1 and or R 2 represent
  • prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivat ives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs” p. 1-92, Elesevier, New York-Oxford (1985).
  • solvate comprises the hydrates and solvent addit ion forms which the compounds of Formula ( I ) are able to form, as well as pharmaceutically acceptable addit ion salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • the compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of cnantiomcrs, that can be separated from one another following art-known resolution procedures.
  • a manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, involves liquid chromatography using a chiral. stationary phase. Said pure
  • stereochemically isomeric forms may also be derived from the corresponding pure stereochemical ⁇ isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • said compound would be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • the present invention also embraces i so to p i ca 11 y- 1 abe 1 ed compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom hav ing an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).
  • isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopical ly enriched form.
  • Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2 H, 3 ⁇ 4, " C, 13 C, 14 C, 13 N, 15 0, ' ⁇ , 18 0, 32 P, 33 P, 35 S, 18 F, 36 Ci, 122 I, 123 I, 125 1, 131 1, 75 Br, 76 Br, 77 Br and 82 Br.
  • the radioactive isotope is selected from the group of 2 H, 3 H, "C and 18 F. More preferably, the radioactive isotope is H.
  • deuterated compounds are intended to be included w ithin the scope of the present invention.
  • Certain i sotop i ca 11 y- 1 abel ed compounds of the present invention are useful for substrate tissue distribution assays. Tritiated ( ⁇ 1 ) and carbon- 14 ( 14 C) isotopes are useful for their ease of preparation and detectability.
  • Positron emitting isotopes such as l 5 0, 13 N, 1 1 C and 18 F are useful for positron emission tomography ( PET) studies to examine substrate receptor occupancy.
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or
  • X represents -0-
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is a monocyclic aromatic ring is selected from the consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci_ 4 alkyl
  • R 4a represents hydrogen, halo, -NR 8a R 8b , or Ci_ 4 alkyl
  • R 8a and R 8b each independently represent hydrogen or Ci- 4 alkyl
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci_ 4 alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci- 4 alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci-4alkyl;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N, said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci_ 4 alkyl
  • R 4a represents hydrogen, halo, -NR 8a R 8b , or Ci_ 4 alkyl;
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl;
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b each independently represent hydrogen, halogen, Ci-4alkyl, -NR 9a R 9b , or Ci_4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-C 1-4 alkyl, -NH 2 , -NH-C 1-4 alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-C 1-4 alkyl, -NHR 10 , cyano, -CF 3 , Ci-4alkyloxy, C 3 -ecycloalkyl, -0-C 3 -ecycloalkyl, C 2 - 6 alkenyl, Ci-4alkyl, and Ci-4alkyl substituted with one Ci-4alkyloxy; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 10 represents C3-6cycloalkyl; R 13 ; R 14 ; C3- 6 cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci-4alkyl; Ci-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and - 0-Ci_4alkyl; or Ci-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R 13 and R 14 ;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl;
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • X represents -0-
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is pyridinyl
  • ring B is a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -NH 2 , -NH-Ci-4alkyl, -CF 3 , C 3 - 6 cycloalkyl, and Ci-4alkyl; and
  • Ar is optionally substituted on one N-atom with one Ci-4alkyl
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen or Ci-4alkyl
  • R 4a represents hydrogen
  • Q 1 represents CR 6a
  • Q 2 represents N or CR 6b ;
  • R 6a and R 6b each independently represent hydrogen or halogen
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or
  • X represents -0-
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is pyridinyl
  • ring B is a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -NH 2 , -NH-Ci-4alkyl, -CF3, C3- 6 cycloalkyl, and Ci-4alkyl;
  • Ar is optionally substituted on one N-atom with one Ci-4alkyl
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen or Ci- 4 alkyl
  • R 4a represents hydrogen
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b each independently represent hydrogen or halogen
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH2-
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or
  • X represents -0-
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • ring A is pyridinyl
  • ring B is a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , -CF 3 , C 3 _ 6 cycloalkyl, and Ci_ 4 alkyl; and
  • Ar is optionally substituted on one N-atom with one Ci_ 4 alkyl
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen or Ci_ 4 alkyl
  • R 4a represents hydrogen
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b each independently represent hydrogen or halogen
  • the present invention concerns novel compounds of Formula (I), wherein
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 1 1 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_4alkyl substituted with one Ci-4alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C 3 - 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci-4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a bicyclic ring system; wherein the bicyclic ring system is
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • fused bicyclic partially aromatic ring system which is attached with the aromatic ring to linker Z, wherein the fused bicyclic partially aromatic ring system is selected from (b-1), (b-2) and (b-3)
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3); R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 6i and R 6j each independently represent hydrogen, halogen, Ci_ 4alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci-4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 1 1 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a fused bicyclic partially aromatic ring system which is attached with the aromatic ring to linker Z, wherein the fused bicyclic partially aromatic ring system is selected from (b-1), (b-2) and (b-3)
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_4alkyl substituted with one Ci-4alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci-4alkyl C 2 _4alkenyl, C 3 - 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R represents hydrogen;
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci- 4 alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci- 4 alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci- 4 alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci- 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci_ 4 alkyl, or Ci- 4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci- 4 alkyl, -NH 2 , -NH-Ci- 4 alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_ 4 alkyl C 2 _ 4 alkenyl, C 3 - 6 cycloalkyl, -OH, or -0-Ci_ 4 alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci_ 4 alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci- 4 alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • Z represents -CR 5c R 5d -CR 5e R 5g -CR 5f R 5h -, or -CR 5a R 5b -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-C 1-4 alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6- membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_4alkyl substituted with one Ci-4alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 _6cycloalkyl substituted with one, two or three halo atoms;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C 3 -6cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 1 1 -;
  • R 1 1 represents hydrogen, Ci_ 4 alkyl, or Ci_ 4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci_ 4 alkyl, -NH 2 , -NH-Ci_ 4 alkyl, and - N(Ci_ 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring or a bicyclic ring system
  • the monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or
  • fused bicyclic partially aromatic ring system which is attached with the aromatic ring to linker Z, wherein the fused bicyclic partially aromatic ring system is selected from (b-1), (b-2) and (b-3)
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl; wherein ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, oxo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system (a-1);
  • R 3a represents -NR 7a R 7b ;
  • R 7a represents hydrogen
  • R 7b represents hydrogen
  • R 4a represents hydrogen
  • Q 1 represents CR 6a
  • Q 2 represents CR 6b
  • R and R represent hydrogen
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl, -0-C 3 _ 6 cycloalkyl, C 2 - 6 alkenyl, Ci-4alkyl, and Ci-4alkyl substituted with one Ci-4alkyloxy;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3); R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 6i and R 6j each independently represent hydrogen, halogen, Ci_ 4alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-C 1-4 alkyl, -NHR 10 , cyano, -CF 3 , Ci-4alkyloxy, C 3 -ecycloalkyl, -0-C 3 -ecycloalkyl, C 2 -6alkenyl, Ci-4alkyl, and Ci-4alkyl substituted with one Ci-4alkyloxy; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms;
  • R 10 represents C 3 _ 6 cycloalkyl; R 13 ; R 14 ; C 3 _ 6 cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci-4alkyl; Ci-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and - 0-Ci_4alkyl; or Ci-4alkyl substituted with one substituent selected from the group consisting of C 3 _6cycloalkyl, R 13 and R 14 ;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_4alkyl C 2 -4alkenyl, C 3 - 6 cycloalkyl, -OH, or -0-Ci-4alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C 3 - 6 cycloalkyl, or Ci-4alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl;
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 11 represents N or CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci-4alkyl, or Ci-4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci-4alkyl, -NH 2 , -NH-Ci-4alkyl, and - N(Ci- 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-Ci_ 4 alkyl,
  • Ci_ 4 alkyloxy C3- 6 cycloalkyl, -0-C3-6cycloalkyl, C 2 -6alkenyl, Ci_ 4alkyl, and Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy;
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C3- 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C3- 6 cycloalkyl substituted with one, two or three halo atoms;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_ 4 alkyl C 2 - 4 alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci_ 4 alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci_ 4 alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci- 4 alkyl
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • Q 8 represents CR 6g ;
  • Q 9 represents CR 6h ;
  • Q 10 represents CR 6i ;
  • Q 11 represents CR 6j ;
  • Q 5 represents CR 3d ;
  • Q 6 represents N; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents CR 3d ;
  • Q 6 represents CR 4e ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci- 4 alkyl
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h represent hydrogen
  • X represents -0-
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -NH 2 , -NH-Ci-4alkyl, -CF 3 , C 3 -6cycloalkyl, and Ci-4alkyl; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl;
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen, or Ci-4alkyl
  • R 4a represents hydrogen
  • Q 1 represents CR 6a
  • Q 2 represents CR 6b ;
  • R 6a and R 6b represent hydrogen, or halogen
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h represent hydrogen
  • X represents -0-
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system selected from the group consisting of
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -NH 2 , -NH- Ci_4alkyl, -CF 3 , C 3 - 6 cycloalkyl, and Ci-4alkyl; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl;
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen, or Ci- 4 alkyl
  • R 4a represents hydrogen
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b represent hydrogen, or halogen; and pharmaceutically acceptable addition salts, and solvates thereof.
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • Z represents -CR 5e R 5g -CR 5i R 5h -;
  • R 5e , R 5f , R 5g , and R 5h represent hydrogen
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -NH 2 , -NH- Ci_4alkyl, -CF 3 , C 3 - 6 cycloalkyl, and Ci-4alkyl;
  • Het represents (a- 1 );
  • R 3a represents -NR 7a R 7b ;
  • R 7a represents hydrogen
  • R 7b represents hydrogen
  • R 4a represents hydrogen
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b represent hydrogen
  • the present invention concerns novel compounds of Formula (I), wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 -
  • Z represents -CR 5e R 5g -CR 5i R 5h -;
  • R 5e , R 5f , R 5g , and R 5h represent hydrogen
  • R 3a represents -NR 7a R 7b ;
  • R 7a represents hydrogen
  • R 7b represents hydrogen
  • R 4a represents hydrogen
  • Q 1 represents CR 6a ;
  • Q 2 represents CR 6b ;
  • R 6a and R 6b represent hydrogen
  • the present invention concerns novel compounds of Formula ( I ), wherein
  • R 1 represents hydrogen
  • R 2 represents hydrogen
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci_ 4 alkyl, or Ci_ 4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci_ 4 alkyl, -NH 2 , -NH-Ci_ 4 alkyl, and - N(Ci_ 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-Ci_ 4 alkyl,
  • Ci_ 4 alkyloxy C3- 6 cycloalkyl, -0-C3-6cycloalkyl, C 2 - 6 alkenyl, Ci_ 4 alkyl, and Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy;
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C3- 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C3- 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
  • R 3a , R 3d and R 3e each independently represent hydrogen, halo, -NR 7a R 7b ,
  • Ci_ 4 alkyl C 2 _ 4 alkenyl, C3- 6 cycloalkyl, -OH, or -0-Ci_ 4 alkyl;
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci_ 4 alkyl
  • R 4a , R 4d , R 4e , R 4f and R 4g each independently represent hydrogen, halo,
  • R 8a and R 8b each independently represent hydrogen or Ci- 4 alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • Q 8 represents N or CR 6g ;
  • Q 9 represents N or CR 6h ;
  • Q 10 represents N or CR 6i ;
  • Q 1 1 represents N or CR 6j ;
  • Q 5 represents N;
  • Q 6 represents CR 4e ; and
  • Q 7 represents CR 4f ; or
  • Q 5 represents N
  • Q 6 represents CR 4e
  • Q 7 represents N
  • Q 5 represents N
  • Q 6 represents N
  • Q 7 represents N
  • R 6a , R 6b , R 6g , R 6h , R 61 and R 6j each independently represent hydrogen, halogen, Ci_ 4 alkyl, -NR 9a R 9b , or Ci-4alkyl substituted with one, two or three halo atoms;
  • R 9a and R 9b each independently represent hydrogen or Ci- 4 alkyl
  • the present invention concerns novel compounds of Formula ( I ). wherein
  • R 1 represents hydrogen or
  • R 2 represents hydrogen or
  • Y represents -CH 2 - or -CF 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h each independently represent hydrogen or Ci_ 4 alkyl;
  • X represents -0-, -S-, or -NR 11 -;
  • R 11 represents hydrogen, Ci_ 4 alkyl, or Ci_ 4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci_ 4 alkyl, -NH 2 , -NH-Ci_ 4 alkyl, and - N(Ci_ 4 alkyl) 2 ;
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-Ci_ 4 alkyl,
  • Ci_ 4 alkyl substituted with one Ci_ 4 alkyloxy;
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci_ 4 alkyl; C 3 - 6 cycloalkyl; Ci_ 4 alkyl substituted with one, two or three halo atoms; and C3- 6 cycloalkyl substituted with one, two or three halo atoms;
  • p 1 or 2;
  • R 14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
  • R 3a represents hydrogen, halo, -NR 7a R 7b , Ci-4alkyl, C 2 _4alkenyl, C3- 6 cycloalkyl, -OH, or
  • R 7a represents hydrogen
  • R 7b represents hydrogen, C3- 6 cycloalkyl, or Ci-4alkyl
  • R 4a represents hydrogen, halo, -NR 8a R 8b , or Ci-4alkyl
  • R 8a and R 8b each independently represent hydrogen or Ci-4alkyl
  • Q 1 represents N or CR 6a ;
  • Q 2 represents N or CR 6b ;
  • R 6a and R 6b each independently represent hydrogen, halogen, Ci-4alkyl, -NR 9a R 9b , or
  • Ci_4alkyl substituted with one, two or three halo atoms
  • R 9a and R 9b each independently represent hydrogen or Ci-4alkyl
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • R 1 and R 2 represent hydrogen
  • Y represents -CH 2 -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h represent hydrogen
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -NH 2 , -NH- Ci_4alkyl, -CF 3 , C 3 - 6 cycloalkyl, and Ci-4alkyl; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl;
  • R 3a represents halo, -NR 7a R 7b , or -0-Ci_ 4 alkyl
  • R 7a represents hydrogen
  • R 7b represents hydrogen, or Ci- 4 alkyl
  • Q 1 represents CR 6a
  • Q 2 represents CR 6b ;
  • R 6a and R 6b represent hydrogen, or halogen.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • R 1 and R 2 represent hydrogen.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present inv ention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents -CH 2 -.
  • the present inv ention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thcreof as mentioned in any of the other embodiments, wherein maximum one of Q and Q 2 represents N.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q 1 represents CR 6A ; and Q2 re p resen t s CR 6B ; in part icular wherein Q 1 represents CH; and Q 2 represents CH.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Het represents (a- 1 ).
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Het represents (a-1); Q 1 represents CR 6A ; and Q 2 represents CR 6B ; in particular wherein Q 1 represents CH; and
  • the present invent ion relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Q 5 represents CR 3D ;
  • Q 6 represents N; and
  • Q 7 represents CR 4F ; or
  • Q 5 represents CR 3D ;
  • Q 6 represents CR 4E ; and
  • Q 7 represents N; or
  • Q 5 represents N;
  • Q 6 represents CR 4E ; and
  • Q 7 represents CR 4F ; or
  • Q 5 represents N
  • Q 6 represents CR 4E
  • Q 7 represents N
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, w herein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a- 1 ) and (a-2).
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutical ly acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system of Formula (a- 1 ).
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein
  • Het represents a bicyclic aromat ic heterocyclic ring system of Formula (a-1);
  • R 1 and R 1 represent hydrogen
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • R 3a , R 3d , R 3e represent hydrogen, halo, -NR 7a R 7b , or -O-CVialkyl; in particular R 3a , R 3d , R 3e represent halo, -NR 7a R 7b , or O-CVialkyl;
  • R 4a , R 4d , R 4e , R 4f and R 4g represent hydrogen.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup t hereof as ment ioned in any of the other embodiments, wherein Ar represents a monocyclic aromatic ring as defined in any other embodiments, or Ar represents a bicyclic ring system according to definition (i) or (ii).
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; or a 9-membered bicyclic aromatic ring system selected from the group consisting of
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a monocyclic aromatic ring selected from 2-pyridinyl, 3-pyridinyl, 4- pyridinyl, lH-imidazol-4-yl and lH-imidazol-5-yl; or a 9-membered bicyclic aromatic ring system selected from the group consisting of
  • whercin Ar is optionally substituted according to any of the embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutical ly acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a monocyclic aromatic ring selected from 2-pyridinyl, 3-pyridinyl, 4- pyridinyl, lH-imidazol-4-yl and lH-imidazol-5-yl; or a 9-membered bicyclic aromatic ring system selected from the group consisting of
  • Ar is substituted in the position indicated by a ( if any) ith -NH 2 , -NH-CV alkyl, or-NHR 10 ; and wherein Ar is optionally substituted with substituents selected from the l ist of substituents on Ar in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; in particular 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, lH-imidazol-4-yl or lH-imidazol-5-yl;
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Ar represents a monocyclic aromatic ring selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl;
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a bicyclic ring system
  • Ar is optionally substituted according to any of the embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solv ates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused
  • 6-membered rings wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or -CR 5a R 5b -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -; wherein Ar is optionally substituted according to any of the embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N, said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring; or
  • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
  • Z can only represent -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h - or -CR 5a R 5b -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -; wherein Ar is optionally substituted according to any of the embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a fused bicyclic partially aromatic ring system which is attached with the aromatic ring to linker Z, wherein the fused bicyclic partially aromatic ring system is selected from (b-1), (b-2) and (b-3),
  • ring A is a monocyclic aromatic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl and imidazolyl;
  • ring B is a Cs ecycloalkyl or a 5- to 6-membered saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S and N;
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 9- membered bicyclic aromatic ring system selected from
  • the present inv ention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solv ates thereof, or any subgroup thercof as mentioned in any of the other embodiments, wherein Ar represents a membered bicyclic aromatic ring system selected from
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a fused bicyclic partially aromatic ring system selected from
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a monocyclic aromatic ring selected from pyridinyl, pyrimidinyl, pyrazolyl, and imidazolyl; or a bicyclic ring system selected from
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Ar represents a 9- membered bicyclic aromatic ring system selected from the group consisting of
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 9- membered bicyclic aromatic ring system selected from the group consisting of
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Ar represents a 9-
  • Ar is substituted in the position indicated by a ( if any) with -NH 2 , -NH-G- 4 alkyl, or-NHR 10 ; and wherein Ar is optionally substituted with substituents selected from the l ist of substituents on Ar in any of the other embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a bicyclic ring system selected from the group consisting of
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Z represents -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -, or -CR 5a R 5b -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i represent hydrogen
  • Ar represents a bicyclic ring system selected from the group consisting of
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutical ly acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Z represents -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -, or -CR 5a R 5b -CR 5c R 5d -CR 5e R 5g -CR 5i R 5h -;
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h , and R 5i represent hydrogen;
  • Ar represents a bicyclic ring system selected from the group consisting of
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Ar is subst ituted with one substituent selected from the group consisting of -NH 2 , -NH-G alkyl,
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thcreof as mentioned in any of the other embodiments, wherein
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-C 1-4 alkyl, -NHR 10 , cyano, -CF 3 , Ci-4alkyloxy, C 3 -ecycloalkyl, -0-C 3 -ecycloalkyl, C 2 -6alkenyl, Ci-4alkyl, and Ci-4alkyl substituted with one Ci-4alkyloxy.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a monocyclic aromatic ring selected from pyridinyl and imidazolyl; wherein Ar is optionally substituted according to any of the embodiments.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N,
  • said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • Ar is optionally substituted on the carbon atoms with in total one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH 2 , -NH-Ci_ 4 alkyl, -NHR 10 , cyano, -CF 3 , Ci_ 4 alkyloxy, C 3 _ 6 cycloalkyl, -0-C 3 _ 6 cycloalkyl, C 2 -6alkenyl, Ci-4alkyl, and Ci-4alkyl substituted with one Ci-4alkyloxy; and
  • Ar is optionally substituted on one N-atom with one substituent selected from the group consisting of Ci-4alkyl; C 3 - 6 cycloalkyl; Ci-4alkyl substituted with one, two or three halo atoms; and C 3 - 6 cycloalkyl substituted with one, two or three halo atoms.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • Ar represents a 9-membered bicyclic aromatic ring system consisting of a 6-membered ring fused with a 5-membered ring, containing one, two or three heteroatoms each independently selected from O, S, and N, said 9-membered bicyclic aromatic ring being attached to the remainder of the molecule via a ring carbon atom of the 5- or 6-membered ring, or a ring nitrogen atom of the 5-membered ring;
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 5b , R 5g and R 5h represent hydrogen.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Q 1 represents CR 6a ; and Q 2 represents CR 6b .
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • R 5b , R 5g and R 5h represent hydrogen
  • Y represents -CH 2 -
  • Het represents (a- 1 );
  • the present invention relates to those compounds of Formula ( I ) and pharmaceut ically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q represents CR 6b .
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein Y represents -CH 2 -
  • the present invent ion relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein
  • R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , and R 5h represent hydrogen;
  • X represents -0-.
  • the present invention relates to those compounds of Formula ( I ) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as ment ioned in any of the other embodiments, wherein

Abstract

La présente invention concerne des nouveaux analogues nucléosidiques substitués par un système cyclique, monocyclique et bicyclique de formule (I) dans laquelle les variables sont telles que définies dans les revendications. Les composés selon la présente invention sont utiles en tant qu'inhibiteurs de PRMT5. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits composés en tant que principe actif, ainsi que l'utilisation desdits composés comme médicament.
PCT/EP2017/074983 2016-10-03 2017-10-02 Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 WO2018065365A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EA201990851A EA201990851A1 (ru) 2017-02-24 2017-10-02 Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
AU2017338269A AU2017338269B2 (en) 2016-10-03 2017-10-02 Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
CN202211277466.7A CN115626935A (zh) 2016-10-03 2017-10-02 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
TNP/2019/000087A TN2019000087A1 (en) 2016-10-03 2017-10-02 Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
US16/336,934 US11098062B2 (en) 2016-10-03 2017-10-02 Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
JP2019517909A JP7101171B2 (ja) 2016-10-03 2017-10-02 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
UAA201904546A UA124074C2 (uk) 2016-10-03 2017-10-02 Аналоги карбануклеозиду, заміщені моноциклічною та біциклічною кільцевою системою, для застосування як інгібіторів prmt5
CN201780061258.4A CN109803971B (zh) 2016-10-03 2017-10-02 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
MX2019003843A MX2019003843A (es) 2016-10-03 2017-10-02 Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
BR112019006414A BR112019006414A2 (pt) 2016-10-03 2017-10-02 análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
EP17781060.3A EP3519413A1 (fr) 2016-10-03 2017-10-02 Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
KR1020197012099A KR102531344B1 (ko) 2016-10-03 2017-10-02 Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
CA3037998A CA3037998A1 (fr) 2016-10-03 2017-10-02 Nouveaux analogues de carbanucleoside substitues par un systeme cyclique, monocyclique et bicyclique destines a etre utilises en tant qu'inhibiteurs de prmt5
IL265718A IL265718B (en) 2016-10-03 2019-03-31 Novel modified carbonucleoside analogs with monocyclic and cyclic ring systems as prmt5 inhibitors
PH12019500731A PH12019500731A1 (en) 2016-10-03 2019-04-03 Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
US17/378,417 US20210371433A1 (en) 2016-10-03 2021-07-16 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors
JP2022033419A JP2022084699A (ja) 2016-10-03 2022-03-04 Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
US18/488,626 US20240124493A1 (en) 2016-10-03 2023-10-17 Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662403336P 2016-10-03 2016-10-03
US62/403,336 2016-10-03
EP17157785 2017-02-24
EP17157785.1 2017-02-24

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US16/336,934 A-371-Of-International US11098062B2 (en) 2016-10-03 2017-10-02 Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US17/378,417 Continuation US20210371433A1 (en) 2016-10-03 2021-07-16 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors
US17/378,417 Division US20210371433A1 (en) 2016-10-03 2021-07-16 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors

Publications (1)

Publication Number Publication Date
WO2018065365A1 true WO2018065365A1 (fr) 2018-04-12

Family

ID=58158964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/074983 WO2018065365A1 (fr) 2016-10-03 2017-10-02 Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5

Country Status (2)

Country Link
EA (1) EA201990851A1 (fr)
WO (1) WO2018065365A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032859A1 (fr) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2019084470A1 (fr) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2020198323A1 (fr) * 2019-03-25 2020-10-01 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
WO2020205867A1 (fr) * 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composés ciblant prmt5
WO2020250123A1 (fr) 2019-06-10 2020-12-17 Lupin Limited Inhibiteurs de prmt5
WO2020249663A1 (fr) 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Nouveaux intermédiaires spirobicycliques
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
JP2021505583A (ja) * 2017-12-05 2021-02-18 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｍｒｔ５阻害剤としての複素環式化合物
WO2021079302A1 (fr) * 2019-10-22 2021-04-29 Lupin Limited Combinaison pharmaceutique d'inhibiteurs de prmt5
WO2021111322A1 (fr) 2019-12-03 2021-06-10 Lupin Limited Analogues nucléosidiques substitués en tant qu'inhibiteurs de prmt5
JP2021515788A (ja) * 2018-03-14 2021-06-24 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
WO2021079196A3 (fr) * 2019-10-21 2021-07-01 Accent Therapeutics, Inc Modulateurs de mettl3
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
WO2021202480A1 (fr) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Composés ciblant prmt5
CN114126614A (zh) * 2019-05-30 2022-03-01 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
WO2022074391A1 (fr) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3
EP3833669A4 (fr) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
AU2018385664B2 (en) * 2017-12-13 2022-06-02 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors
JP7446282B2 (ja) 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040686A1 (fr) 1995-06-07 1996-12-19 Abbott Laboratories Composes de cyclopentane substitue heterocycliques
WO2003070739A1 (fr) 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Agonistes partiels et complets des recepteurs de l'adenosine a1
WO2003074083A1 (fr) 2002-03-04 2003-09-12 Pfizer Inc. Polytherapies pour traiter des cellules a deficience en methylthioadenosine phosphorylase
WO2012075500A2 (fr) 2010-12-03 2012-06-07 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
WO2012082436A2 (fr) 2010-12-03 2012-06-21 Epizyme, Inc. Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
WO2014100719A2 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2014100695A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2014100730A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de la prmt5 contenant une dihydro- ou tétrahydro-isoquinoléine et leurs utilisations
WO2015200680A2 (fr) 2014-06-25 2015-12-30 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20160244475A1 (en) 2015-02-24 2016-08-25 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents
WO2017032840A1 (fr) 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Nouveaux analogues nucléosidiques substitués par un cycle aromatique bicyclique 6-6 utiles comme inhibiteurs de prmt5

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040686A1 (fr) 1995-06-07 1996-12-19 Abbott Laboratories Composes de cyclopentane substitue heterocycliques
WO2003070739A1 (fr) 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Agonistes partiels et complets des recepteurs de l'adenosine a1
WO2003074083A1 (fr) 2002-03-04 2003-09-12 Pfizer Inc. Polytherapies pour traiter des cellules a deficience en methylthioadenosine phosphorylase
WO2012075500A2 (fr) 2010-12-03 2012-06-07 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
WO2012082436A2 (fr) 2010-12-03 2012-06-21 Epizyme, Inc. Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
WO2014100719A2 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2014100695A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2014100730A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de la prmt5 contenant une dihydro- ou tétrahydro-isoquinoléine et leurs utilisations
WO2015200680A2 (fr) 2014-06-25 2015-12-30 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20160244475A1 (en) 2015-02-24 2016-08-25 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents
WO2016135582A1 (fr) 2015-02-24 2016-09-01 Pfizer Inc. Dérivés de nucléosides substitués utiles en tant qu'agents anticancéreux
WO2017032840A1 (fr) 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Nouveaux analogues nucléosidiques substitués par un cycle aromatique bicyclique 6-6 utiles comme inhibiteurs de prmt5

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ANDREU-PEREZ, P. ET AL., SCI SIGNAL, vol. 4, no. 190, 2011, pages ra58
ANTONYSAMY, S. ET AL., PROC NATL ACAD SCI USA, vol. 109, no. 44, 2012, pages 17960 - 5
BEZZI, M. ET AL., GENES DEV, vol. 27, no. 17, 2013, pages 1903 - 16
BUNDEGAARD, H.: "Design of Prodrugs", 1985, ELESEVIER, pages: 1 - 92
CHAN-PENEBRE, E. ET AL., NAT CHEM BIOL, vol. 11, no. 6, 2015, pages 432 - 7
DEVKOTA, K. ET AL., ACS MED CHEM LETT, vol. 5, 2014, pages 293 - 297
DI LORENZO, A., FEBS LETT, vol. 585, no. 13, 2011, pages 2024 - 31
FRIESEN, W.J. ET AL., MOL CELL BIOL, vol. 21, no. 24, 2001, pages 8289 - 300
GEOGHEGAN, V. ET AL., NAT COMMUN, vol. 6, 2015, pages 6758
GU, Z. ET AL., BIOCHEM J, vol. 446, no. 2, 2012, pages 235 - 41
HSU, J.M. ET AL., NAT CELL BIOL, vol. 13, no. 2, 2011, pages 174 - 81
JANSSON, M. ET AL., NAT CELL BIOL, vol. 10, no. 12, 2008, pages 1431 - 9
KARKHANIS, V. ET AL., TRENDS BIOCHEM SCI, vol. 36, no. 12, 2011, pages 633 - 41
KUNG P P ET AL: "Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 15, no. 11, 2 June 2005 (2005-06-02), pages 2829 - 2833, XP025313694, ISSN: 0960-894X, [retrieved on 20050602], DOI: 10.1016/J.BMCL.2005.03.107 *
KUNG, P.-P. ET AL., BIOORG MED CHEM LETT, vol. 15, 2005, pages 2829 - 2833
PAL, S. ET AL., EMBO J, vol. 26, no. 15, 2007, pages 3558 - 69
SHILO, K. ET AL., DIAGN PATHOL, vol. 8, 2013, pages 201
STOPA, N. ET AL., CELL MOL LIFE SCI, vol. 72, no. 11, 2015, pages 2041 - 59
TETRAHEDRON, vol. 58, 2002, pages 8255 - 8262
WANG, L. ET AL., MOL CELL BIOL, vol. 28, no. 20, 2008, pages 6262 - 77
WEI, H. ET AL., PROC NATL ACAD SCI USA, vol. 110, no. 33, 2013, pages 13516 - 21
WEI, T.Y. ET AL., CELL SIGNAL, vol. 26, no. 12, 2014, pages 2940 - 50
ZHAO, Q. ET AL., NAT STRUCT MOL BIOL, vol. 16, no. 3, 2009, pages 304 - 11

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318157B2 (en) 2015-08-26 2022-05-03 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US11883367B2 (en) 2015-08-26 2024-01-30 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
US10570140B2 (en) 2017-08-09 2020-02-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11078205B2 (en) 2017-08-09 2021-08-03 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
EP3939986A1 (fr) 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2019032859A1 (fr) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US11208416B2 (en) 2017-08-09 2021-12-28 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
WO2019084470A1 (fr) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
JP2021505583A (ja) * 2017-12-05 2021-02-18 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｍｒｔ５阻害剤としての複素環式化合物
AU2018381004B2 (en) * 2017-12-05 2021-04-29 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
US11702441B2 (en) 2017-12-08 2023-07-18 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
AU2018385664B2 (en) * 2017-12-13 2022-06-02 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
JP2021515788A (ja) * 2018-03-14 2021-06-24 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
JP7328241B2 (ja) 2018-03-14 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11214574B2 (en) 2018-03-14 2022-01-04 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11254683B2 (en) 2018-03-14 2022-02-22 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
EP3833669A4 (fr) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
JP7446282B2 (ja) 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
WO2020198323A1 (fr) * 2019-03-25 2020-10-01 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
EP3947387A4 (fr) * 2019-03-25 2022-11-30 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
CN114127072A (zh) * 2019-03-25 2022-03-01 加利福尼亚技术学院 Prmt5抑制剂及其用途
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2020205867A1 (fr) * 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composés ciblant prmt5
CN114072407A (zh) * 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
CN114126614A (zh) * 2019-05-30 2022-03-01 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors
WO2020250123A1 (fr) 2019-06-10 2020-12-17 Lupin Limited Inhibiteurs de prmt5
WO2020249663A1 (fr) 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Nouveaux intermédiaires spirobicycliques
WO2021079196A3 (fr) * 2019-10-21 2021-07-01 Accent Therapeutics, Inc Modulateurs de mettl3
WO2021079302A1 (fr) * 2019-10-22 2021-04-29 Lupin Limited Combinaison pharmaceutique d'inhibiteurs de prmt5
WO2021111322A1 (fr) 2019-12-03 2021-06-10 Lupin Limited Analogues nucléosidiques substitués en tant qu'inhibiteurs de prmt5
WO2021202480A1 (fr) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Composés ciblant prmt5
WO2022074391A1 (fr) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3

Also Published As

Publication number Publication date
EA201990851A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
WO2018065365A1 (fr) Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
US11883367B2 (en) 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
AU2017230658B2 (en) Substituted nucleoside analogues for use as PRMT5 inhibitors
AU2017338269B2 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US11059850B2 (en) Spirobicyclic analogues
US10898504B2 (en) Substituted nucleoside analogues for use as PRMT5 inhibitors
OA18631A (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors.
EA044355B1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17781060

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3037998

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 265718

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2019517909

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017338269

Country of ref document: AU

Date of ref document: 20171002

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019006414

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197012099

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017781060

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112019006414

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190329